



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

## Public Summary

|                                |  |               |
|--------------------------------|--|---------------|
| <b>Summary for ARTG Entry:</b> | 227245   | D3 + K2 Spray |
| <b>ARTG entry for</b>          | Medicine Listed  |               |
| <b>Sponsor</b>                 | FIT-BioCeuticals Limited   |               |
| <b>Postal Address</b>          | Care of Blackmores Ltd PO Box 1725, Warriewood, NSW, 2102<br>Australia |               |
| <b>ARTG Start Date</b>         | 25/08/2014   |               |
| <b>Product Category</b>        | Medicine   |               |
| <b>Status</b>                  | Active   |               |
| <b>Approval Area</b>           | Listed Medicines   |               |

### Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

### Products

#### 1 . D3 + K2 Spray

|                     |                         |                       |            |
|---------------------|-------------------------|-----------------------|------------|
| <b>Product Type</b> | Single Medicine Product | <b>Effective Date</b> | 23/04/2020 |
|---------------------|-------------------------|-----------------------|------------|

### Permitted Indications

Maintain/support teeth mineralisation  
Maintain/support bone health  
Aids/assists healthy bone development/growth/building in aging individuals  
Aids/assists healthy bone development/growth/building  
Maintain/support bone strength in aging individuals  
Maintain/support bone strength  
Help maintain/support bone mineralisation  
Help maintain/support bone mineralisation in aging individuals  
Maintain/support healthy cardiovascular system function  
Maintain/support artery health  
Maintain/support healthy immune system function  
Maintain/support absorption of dietary (state vitamin/mineral/nutrient)  
Maintain/support (state vitamin/mineral/nutrient) levels in the body  
Maintain/support nervous system function

### Indication Requirements

Product presentation must not imply or refer to circulatory disorders/diseases/conditions e.g. thrombosis.

Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis. Note: this requirement is not intended to apply where the indications referring to osteoporosis specified in column 2 of Table 2 of this instrument are also used.

If product is indicated for supplementation, Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Product presentation must not imply or refer to mental illnesses, disorders or conditions.

Product presentation must not imply or refer to serious cardiovascular conditions.

Public Summary



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

Product presentation must not imply or refer to serious immunological diseases.

Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

**Standard Indications**

No Standard Indications included on Record

**Specific Indications**

No Specific Indications included on Record

**Warnings**

No Warnings included on Record

**Additional Product information**

**Pack Size/Poison information**

**Pack Size**

**Poison Schedule**

**Components**

**1 . Formulation 1**

**Dosage Form** Oral Liquid

**Route of Administration** Oral

**Visual Identification**

**Active Ingredients**

colecalfiferol .1387 mg/mL

menaquinone 7 250 microgram/mL

**Other Ingredients (Excipients)**

dl-alpha-tocopherol

medium chain triglycerides

Rice bran oil

vegetable oil

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary